MMPAD

 

 

A message from the Programme Director…

With diagnoses of type 1 diabetes in Europe on the rise, healthcare professionals face increasing challenges in the prevention and management of paediatric diabetes as well as keeping on top of the latest research.

In partnership with Springer Healthcare IME, I am delighted to present this blended programme which has been developed to provide healthcare professionals with improved knowledge and tools on the diagnosis, management and prevention of the condition, also covering both the acute and chronic complications.

The programme will be of keen interest to paediatricians, diabetologists and general practitioners as well as specialist nurses who are involved in the day-to-day management of the disease.

I will be coordinating this European Programme in collaboration with an international scientific faculty to present an engaging and thought-leading programme.

We look forward to seeing you at one of our live meetings across Europe.

Professor Francesco Chiarelli
University of Chieti, Italy

 

Past events

Panel Discussion at 57th ESPE meeting – Megaron Athens International Conference Centre – Athens, Greece
Sep 29 @ 8:00 am – 8:45 am


 

European Roadshow – Hôtel Saint James Albany – Paris, France
Sep 7 @ 9:00 am – 4:00 pm


 

European Roadshow – The Royal Society – London, UK
Jul 20 @ 9:00 am – 4:00 pm


 

European Roadshow – Palazzo dei Giureconsulti – Milan, Italy
Jun 29 @ 9:30 am – 4:30 pm


 

European Roadshow – Hotel Emperador – Madrid, Spain
Jun 15 @ 10:30 am – 5:30 pm


 

European Roadshow – Hotel Vier Jahreszeiten Kempinski – Munich, Germany
May 25 @ 10:00 am – 5:00 pm


 

 

Independent Medical Education Provider

Springer Healthcare IME is part of Springer Healthcare Ltd., which is part of the Springer Nature group. The IME business unit develops independent medical education resources, events and expert-led content through sponsorship from grant providers.

Educational grant

This programme is made possible thanks to an independent educational grant from Novo Nordisk A/S.